MedReleaf Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter Ended September 30, 2017

Nov 13 17

MedReleaf Corp. announced unaudited consolidated earnings results for the second quarter ended September 30, 2017. For the quarter, the company reported total sales of CAD 9,821,000 compared to CAD 10,749,000 a year ago. Sales of dried cannabis for the second quarter of fiscal 2018 were CAD 7.7 million, a decrease of 27% from the prior year period due to the impact of volume and price restrictions imposed by VAC. Adjusted EBITDA was CAD 685,000 compared to CAD 4,650,000 a year ago. Due to the impact of the VAC policy change, overhead costs associated with the Bradford facility construction and operating investments towards future growth. Net loss was CAD 2,126,000 compared to net income was CAD 3,740,000 a year ago. Diluted loss per share were CAD 0.02 compared with earnings per share were CAD 0.05 a year ago. Cash flow used in operating activities for the six months ended September 30, 2017 was CAD 5.3 million compared cash flow provided by operating activities of CAD 6.4 million for the prior year period. The decrease in cash flow provided by operating activities was mainly due to IPO related costs (CAD 2.6 million) and increased operating costs that were partially offset by increased sales and gross profit.

MedReleaf Corp. Receives License Amendment from Health Canada to Commence Sales at its Bradford Facility

Nov 6 17

MedReleaf Corp. has been granted an amended license from Health Canada to permit sales of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) at its second facility in Bradford, ON (“Bradford Facility”). This increases the Company’s total current licensed production and sales capacity by 80% to approximately 12,600 kg per year. This latest amended license from Health Canada follows several other recent milestones at the Bradford Facility. On October 11, 2017, MedReleaf received its amended licence for the use of its Mother Room and Clone Room which will support the growing capacity at the Bradford Facility. On October 20, 2017, the Company received an amended licence for the use of two additional cultivation rooms, effectively doubling annual production capacity to an estimated 5,600 kg at the Bradford Facility. Once construction of the Bradford Facility is fully completed in the summer of 2018, total licensed production and sales capacity from MedReleaf’s two facilities in Markham and Bradford will be 35,000 kg per year.

Ehave, Inc. Advances MedReleaf Corp. Collaboration with Launch of Digital Patient Intake Portal

Nov 1 17

Ehave, Inc. announced the launch of a robust digital patient intake system, in collaboration with MedReleaf Corp. to facilitate the objective clinical assessment and optimization of cannabis-based therapies for treating a variety of health conditions. Ehave’s technology will be integrating with MedReleaf’s patient and physician dashboard that is used to establish baseline patient assessments and track patient-reported symptoms by incorporating a broad panel of clinically-validated surveys into a single digital portal.